Interleukin-13 inhibition by tralokinumab reduces inducible T-cell costimulator-positive innate lymphoid cells in skin lesions of atopic dermatitis

Br J Dermatol. 2023 Jan 23;188(1):146-148. doi: 10.1093/bjd/ljac008.

Affiliations

¹ Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
² LEO Pharma A/S, Ballerup, Denmark.
³ Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.

PMID: 36689531
DOI: 10.1093/bjd/ljac008

No abstract available

MeSH terms

Dermatitis, Atopic* / pathology
Humans
Immunity, Innate
Interleukin-13
Lymphocytes
Skin / pathology
Skin Diseases* / pathology
T-Lymphocytes / pathology

Substances

Interleukin-13
tralokinumab